EUVIMEDEUVIMED entdecken
Crossref

Maternal Vaccination and Protective Immunity Against SARS‐CoV‐2 Infection in Pups

Kunpeng Liu, Juhong Rao, Xue Hu, Huize Sun, Mingqing Lu, Xiaoyu Zhang, Fang Huang iD, Chao Shan iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Kunpeng Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of the Chinese Academy of Sciences, Beijing, Beijing, China. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Immunity, Maternally-Acquired. Die Arbeit nennt 56 Literaturangaben. Gefördert von: This study was supported by National Key Research and Development Program of China (Grants 2024YFC2607300), Hubei Central Leading Local Science and Technology….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has had a devastating impact worldwide. Currently, several vaccines are approved for emergency use in humans, and these vaccines have played a large role in controlling COVID‐19. Pregnant women and newborns constitute a special population for vaccine policy. Here, we established a maternal vaccination model by injecting pregnant mice with a SARS‐CoV‐2 receptor‐binding domain (RBD) homodimer. Maternal immunization with the RBD dimer did not cause obvious adverse effects on pregnancy or fetal development. Moreover, two‐shot immunization fully protected dams and fetuses from SARS‐CoV‐2 infection during pregnancy. Neutralizing antibodies can be transferred from immunized dams to pups, providing protection for both lactating and weaned pups against SARS‐CoV‐2 infection. Our results indicate that, in addition to being used to vaccinate nonpregnant individuals, the RBD dimer can also be considered for maternal vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2COVID-19 VaccinesImmunity, Maternally-AcquiredPregnancy Complications, InfectiousAnimalsFemalePregnancyMiceAntibodies, NeutralizingAntibodies, ViralVaccinationHumansSpike Glycoprotein, CoronavirusMice, Inbred BALB CAnimals, NewbornDisease Models, Animal

Stichwörter der Autor:innen

IAVRBDSARS‐CoV‐2pregnancypups

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • University of the Chinese Academy of Sciences, Beijing, Beijing, China.
  • Hubei Jiangxia Laboratory, Wuhan, Hubei, China.
  • Hubei University of Chinese Medicine, Wuhan, Hubei, China.
  • Hangzhou Medical College, Hangzhou, Zhejiang, China.

ORCID-Profile: Fang Huang, Chao Shan

Förderung

  • This study was supported by National Key Research and Development Program of China (Grants 2024YFC2607300), Hubei Central Leading Local Science and Technology…

Zitieren

APA

Liu, K., Rao, J., Hu, X., Sun, H., Lu, M., Zhang, X., Huang, F., & Shan, C. (2025). Maternal Vaccination and Protective Immunity Against SARS‐CoV‐2 Infection in Pups. Journal of Medical Virology. https://doi.org/10.1002/jmv.70418

Vancouver

Liu K, Rao J, Hu X, Sun H, Lu M, Zhang X, et al. Maternal Vaccination and Protective Immunity Against SARS‐CoV‐2 Infection in Pups. Journal of Medical Virology. 2025. doi:10.1002/jmv.70418

BibTeX
@article{Liu2025,
  author = {Liu, Kunpeng and Rao, Juhong and Hu, Xue and Sun, Huize and Lu, Mingqing and Zhang, Xiaoyu and Huang, Fang and Shan, Chao},
  title = {Maternal Vaccination and Protective Immunity Against SARS‐CoV‐2 Infection in Pups},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70418}
}
Kostenlos starten →